Compare · AMGN vs MAZE
AMGN vs MAZE
Side-by-side comparison of Amgen Inc. (AMGN) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $234.65B, about 153.7x MAZE ($1.53B).
- MAZE has been more active in the news (6 items in the past 4 weeks vs 3 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 8 for MAZE).
- Company
- Amgen Inc.
- Maze Therapeutics Inc.
- Price
- -
- -
- Market cap
- $234.65B
- $1.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2025
- News (4w)
- 3
- 6
- Recent ratings
- 25
- 8
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- FDA Approval for REPATHA issued to AMGEN INC
- FDA Approval for RIABNI issued to AMGEN INC
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
- FDA Approval for IMDELLTRA issued to AMGEN INC
- FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
- AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Amgen downgraded by BMO Capital Markets with a new price target
- New insider Dittrich Thomas J.W. claimed ownership of 16,860 shares (SEC Form 3)
Latest MAZE
- SEC Form 8-K filed by Maze Therapeutics Inc.
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
- Chief Executive Officer Coloma Jason V sold $932,260 worth of shares (34,501 units at $27.02) as part of a pre-agreed trading plan (SEC Form 4)
- President, R&D & CMO Bernstein Harold exercised 16,141 shares at a strike of $10.42 and sold $434,743 worth of shares (16,141 units at $26.93) as part of a pre-agreed trading plan (SEC Form 4)
- CSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $202,921 worth of shares (7,500 units at $27.06) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Maze Therapeutics Inc.
- Citigroup initiated coverage on Maze Therapeutics with a new price target
- President, R&D & CMO Bernstein Harold sold $254,502 worth of shares (9,705 units at $26.22) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- GC and Corp. Secretary Courtney Phillips converted options into 11,000 shares (SEC Form 4)
- Chief Executive Officer Coloma Jason V sold $906,999 worth of shares (34,501 units at $26.29) as part of a pre-agreed trading plan and converted options into 50,000 shares (SEC Form 4)